# αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

> **NCT02151448** · PHASE1,PHASE2 · COMPLETED · sponsor: **David Bartlett** · enrollment: 64 (actual)

## Conditions studied

- Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface
- Malignant Peritoneal Mesothelioma
- Peritoneal Carcinomatosis

## Interventions

- **BIOLOGICAL:** DC vaccine
- **DRUG:** Celecoxib
- **DRUG:** Interferon Alfa-2b
- **BIOLOGICAL:** rintatolimod

## Key facts

- **NCT ID:** NCT02151448
- **Lead sponsor:** David Bartlett
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2019-02-18
- **Final completion:** 2019-02-18
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02151448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02151448, "αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02151448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*